Román Rodriguez Milán

β-Blocker Discontinuation after Myocardial Infarction without Reduced Ejection Fraction in the Revascularization Era: A Design-Coherent Bayesian Review & Meta-Analysis

In contemporary revascularized patients with preserved or mildly reduced EF, β-blocker discontinuation was not associated with a credible increase in death or MACE, whether stopped in the stable phase or the acute-withdrawal phase; the prior harm likely reflects immortal-time bias and inclusion of non-revascularized pa...